Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(38)
•••
Comment by Hideawayon Jun 02, 2019 10:53am
150 Views
Post# 29792183

RE:Re: ASCO Investor Webcast

RE:Re: ASCO Investor WebcastVery impressed with conference call details and the confidence all presenters appeared to express. If we can maintain similar or better results from the Merck trials,we would be well on our way to having a blockbuster .
These results combined with a positive report from Merck on the 12th,should provide Wells Fargo with ample ammunition to aggressively promote IMV now that the 90 days are up to allow them to spread the news to US investors.
Exciting times ahead for IMV.
GLTA
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities